A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM) Protocol Amendment 02 - Germany specific - CheckMate143

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2014
This article has no abstract
Epistemonikos ID: 6348225112efdd8fc4e154601c6d88ba08c1bbd0
First added on: Apr 17, 2025